Overview

A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors

Status:
RECRUITING
Trial end date:
2029-08-01
Target enrollment:
Participant gender:
Summary
Phase I: To evaluate the safety, tolerance and effectiveness of IAP0971 for the treatment of advanced malignant tumors. Phase II: Evaluation of IAP0971 therapy driver negative and PD-L1 positive (TPS≥50%) The initial treatment is effective in subjects with advanced or metastatic non-small cell lung cancer.
Phase:
PHASE1
Details
Lead Sponsor:
SUNHO(China)BioPharmaceutical CO., Ltd.